Clinical trials: China
HER2-negative Breast Cancer
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
This is a Phase 2, open-label, multi-center study of BGB-290 administered orally (PO) twice daily (BID) in adult Chinese patients with advanced HER2(-) breast cancer harboring germline BRCA mutation, which have progressed despite…
- Trial name
- NCT03575065
- Testing
- BGB-290
- Where
- 20 sites in China
- Volunteers
- 88 people
- Sponsor
- BeiGene
Type 2 Diabetes
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy
This is a prospective, randomized (open label), multi-center and post-market study. The study is to compare effectiveness of sensor-augmented pump (SAP) therapy versus multiple daily injection (MDI) therapy in hospitalized…
- Trial name
- NCT01921322
- Testing
- Pump, CGMS Gold
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Medtronic MiniMed, Inc.
Rheumatoid Arthritis
An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.
This observational study will describe the treatment patterns of usage of biological DMARDs in routine clinical practice and the demographics and RA disease characteristics in patients suffering from rheumatoid arthritis.
- Trial name
- NCT02590562
- Testing
- Routine clinical practice
- Where
- 15 sites in China
- Volunteers
- 808 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
The objective of this study was to assess the effectiveness of adalimumab on health and disability outcomes in participants with rheumatoid arthritis (RA) in China.
- Trial name
- NCT02668640
- Testing
- Adalimumab
- Volunteers
- 55 people
- Sponsor
- AbbVie
Biliary Tract Carcinoma
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma.
- Trial name
- NCT04924062
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 22 sites in China
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Metastatic Hormone Sensitive Prostate Cancer
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC).
- Trial name
- China ARCHES (NCT04076059)
- Testing
- Enzalutamide, Androgen deprivation therapy (ADT)
- Where
- 28 sites in China
- Volunteers
- 180 people
- Sponsor
- Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Generalized Anxiety Disorder
Duloxetine for the Treatment of Generalized Anxiety Disorder
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
- Trial name
- NCT00803361
- Testing
- Duloxetine
- Where
- 7 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a…
- Trial name
- NCT03486457
- Testing
- Tofacitinib
- Where
- 38 sites in China
- Volunteers
- 204 people
- Sponsor
- Pfizer
Hepatitis B Vaccine
Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Uptake, adherence, and completion of vaccination among HIV-infected adults were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis…
- Trial name
- HIV (NCT03316807)
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 182 people
- Sponsor
- Suping Wang
Relapsing Multiple Sclerosis (RMS)
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT04667949
- Testing
- Fingolimod 0.5mg
- Where
- 13 sites in China
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Aortic Stenosis, Symptomatic Aortic Stenosis
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are…
- Conditions
- Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
- Trial name
- NCT03466918
- Testing
- SAPIEN 3 THV with the Commander delivery system
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Edwards Lifesciences
ALK or ROS1-positive NSCLC
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.
- Trial name
- NCT03672643
- Testing
- Crizotinib
- Where
- 14 sites in China
- Volunteers
- 41 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled…
- Trial name
- NCT02008682
- Testing
- liraglutide, sitagliptin
- Where
- 25 sites in China
- Volunteers
- 368 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable sulfonylurea alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590771
- Testing
- Sitagliptin, Gliclazide, Glimepiride
- Volunteers
- 498 people
- Sponsor
- Merck Sharp & Dohme LLC
Japanese Encephalitis, Japanese Encephalitis Virus Disease
Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
The purpose of this study is to compare Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) with Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine [CD.JEVAX™]) after a single dose vaccination to…
- Trial name
- NCT01396512
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
- Where
- 6 sites in South Korea
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV
Crowdsourcing A Public Health Campaign
The purpose of this stepped wedge randomized controlled trial is to evaluate the effectiveness of a crowdsourced intervention on promoting HIV testing among young Chinese men who have sex with men (MSM).
- Trial name
- NCT02796963
- Testing
- Crowdsourced intervention, Traditional intervention campaign
- Volunteers
- 1,381 people
- Sponsor
- University of North Carolina, Chapel Hill
Hypoxic-Ischemic Encephalopathy
Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy
The purpose of this study is to investigate the effectiveness and safety of selective head cooling (SHC) in neonatal hypoxic-ischemic encephalopathy (HIE).
- Trial name
- NCT00890409
- Testing
- Cooling cap (YJW608-04B)
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Environmental Carcinogenesis
Broccoli Sprout Intervention in Qidong, P.R. China
This study is a 12 week placebo-controlled Phase II broccoli sprout intervention to be conducted in Qidong, P.R. China. One thousand two hundred people from the farming townships will be screened and three hundred eligible…
- Trial name
- NCT01437501
- Testing
- Broccoli Sprout Extract Beverage
- Where
- China
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cardiovascular Diseases
SYNERGY China: Assess SYNERGY Stent in China
Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.
- Trial name
- NCT02499692
- Testing
- SYNERGYTM Coronary Stent System
- Where
- 8 sites in China
- Volunteers
- 103 people
- Sponsor
- Boston Scientific Corporation